Carregant...
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, ve...
Guardat en:
| Publicat a: | Pharmacoecon Open |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710317/ https://ncbi.nlm.nih.gov/pubmed/30680676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0115-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|